Global Allergic Conjunctivitis Drugs Market – Industry Trends and Forecast to 2030

Global Allergic Conjunctivitis Drugs Market, By Type (Bacterial, Viral, Allergic and Chemical), Drug Class (Antibiotics, Mast Cells Stabilizers, Steroids and Others), Route Of Administration (Topical, oral, Intra-Vitreal and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Allergic Conjunctivitis Drugs Market Analysis and Size

It is witnessed that more than 20% of the global population is largely affected by eye condition called allergic conjunctivitis. Even though these symptoms can look like signs of an infection, allergic conjunctivitis is not infectious or contagious. Allergic conjunctivitis is quite common. Treatment for allergic conjunctivitis include oral medications, eye drops or immunotherapy. The increase in prevalence of allergic conjunctivitis is projected to drive the global allergic conjunctivitis market growth during the forecast period.

 Data Bridge Market Research analyses a growth rate in the global allergic conjunctivitis drugs market in the forecast period 2023-2030. The expected CAGR of global hypersensitivity market is tend to be around 5.90% in the mentioned forecast period. The market was valued at USD 3724.2 million in 2022, and it would grow upto USD 5891.16 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Allergic Conjunctivitis Drugs Market Scope and Segmentation

Market Definition

Allergic conjunctivitis is a type of eye disorder that is characterized by inflammation in the conjunctiva because of allergens, pollen grain, dust mites, cosmetics, chemicals and perfumes. It is also commonly known as pink eye that leads to swell the outer membrane of eyeball. It does not cause any other serious health problems if diagnosed and treated at early stages. The common symptoms include gritty feelings in the eye, abnormal tears amount, itchiness in eyes, thick discharges that form up in the eye during night time and pink or red colour toned eyes.

Global Allergic Conjunctivitis Drugs Market Dynamics

Drivers

• Increase in Allergic conjunctivitis

The rise in prevalence of allergic conjunctivitis is projected to boost the global allergic conjunctivitis market growth during the forecast period. For instance, according to Clinical Epidemiology and Global Health, in India, the incidence of allergic conjunctivitis was around 12.22%, whereas allergic conjunctivitis was recorded in more males (13.44%) compared to females (10.71%) in 2019. This boost the market growth.

• Growing R&D Activities

Major market players operating in the market are focusing on the development of treatments for allergic conjunctivitis, this is projected to boost the global allergic conjunctivitis market growth during the forecast period. For instance, in April 2020, Ocular Therapeutix, Inc., a biopharmaceutical company focused on the development, formulation, and commercialization of innovative therapies for diseases and conditions of the eye, declared topline results from its Phase 3 clinical trial to assess the safety and efficacy of DEXTENZA used for the treatment of ocular itching related with allergic conjunctivitis (AC).

Opportunities

• Higher Growth on Product Launches

Major market players operating in the global allergic conjunctivitis market are primarily focusing on adoption of growth strategies such as product launch, regulatory approval, and R&D for the treatment of allergic conjunctivitis, that are expected to drive the market growth during the forecast period. For instance, in March 2020, Eyevance Pharmaceuticals, a provider of ophthalmic products and therapies intended to address unmet medical needs, announced the U.S. launch of Zerviate 0.24% for treating ocular itching related with allergic conjunctivitis.

• Increasing Demand for Retail Pharmacies

The increase in the number of allergic conjunctivitis drugs therapeutics delivered through retail pharmacies and the rise in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients choose retail pharmacies for purchasing drugs, as these are easily available.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified healthcare professional unable to treat the patients with appropriate eye lubricants could restrain the growth of the global allergic conjunctivitis drugs market over a forecast period.

• Risk of Side-Effects

The side effects associated with the allergic conjunctivitis drugs that comes with the application of drugs of allergic conjunctivitis drugs impedes the market growth. Severe side-effects such as eye pain, change in vision, continued eye redness or irritation and severe side effects such as allergy hampers the market's growth.

This global allergic conjunctivitis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global allergic conjunctivitis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Allergic Conjunctivitis Drugs Market   

The COVID-19 pandemic significantly impacted the pharmaceutical industry's entire supply chain, mostly because of the strict lockdown in several regions. Furthermore, the demand for conjunctivitis drugs is growing in this COVID-19 pandemic, because of the increasing number of conjunctivitis cases, in which it has been seen that conjunctivitis was the only symptom in COVID-19 positive patients. Thus, this will significantly impact the global allergic conjunctivitis drugs market.

Global Allergic Conjunctivitis Drugs Market Scope

The global allergic conjunctivitis drugs market is segmented on the basis of drug class, type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Bacterial
• Viral
• Allergic
• Chemical

Drug Class

• Antibiotics
• Mast Cells Stabilizers
• Steroids
• Others

Route of Administration

• Topical
• Oral
• Intra-Vitreal
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Allergic Conjunctivitis Drugs Market Regional Analysis/Insights

The global allergic conjunctivitis drugs market is analyzed and market size insights and trends are provided by drug class, type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global allergic conjunctivitis drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global allergic conjunctivitis drugs market throughout the forecasted period due to increased new research and developments on allergic conjunctivitis drugs market.

North America dominates the market due to the presence of key manufacturers of the product is high and, increasing research and development activities, healthcare expenditure

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Global Allergic Conjunctivitis Drugs Market Share Analysis

The global allergic conjunctivitis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related global allergic conjunctivitis drugs market.

Key players operating in the global allergic conjunctivitis drugs market include:

• Merck & Co. Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bayer AG (Germany)
• Novartis AG (Switzerland)
• Endo International plc (Ireland)
• Lupin (India)
• Cipla Inc (India)
• Akorn Operating Company (U.S.)
• Bausch &Lomb (Canada)
• Perrigo Company plc (Ireland)
• Hoffmann-La Roche Ltd (Switzerland)
• AbbVie Inc. (U.S.)
• Bausch Health Companies Inc. (Canada)